For its second fiscal quarter (ending June 30), Zevra Therapeutics Inc (NASDAQ: ZVRA) has reported E.P.S. of $-0.48 compared to $-0.08 a year ago. E.P.S. were $-1.71 for the latest four quarters through June 30 versus $-0.91 for the same period a year ago.
Recent Price Action
On 8/13/24, Zevra Therapeutics Inc (NASDAQ: ZVRA) stock declined slightly by -0.4%, closing at $6.78. This decline was accompanied by normal trading volume. The stock has declined -14.0% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
ZVRA is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Zevra Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Zevra Therapeutics has a poor Power Rating of 29 and a very low Appreciation Score of 2, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment